Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3210802 | 0.94 | RAB9A (0.55) | RAB9ANPC1MAPTTP53CHEK1 | |
| SCHEMBL13490686 | 0.86 | CXCR6 (0.46) | RAB9ACHEK1CXCR6 | |
| SCHEMBL13490608 | 0.86 | CHEK1 (0.47) | RAB9ANPC1CHEK1CXCR6POLB | |
| SCHEMBL14192836 | 0.85 | CHEK1 (0.46) | CHEK1CXCR6 | |
| SCHEMBL13490663 | 0.84 | SMN1; SMN2 (0.47) | CHEK1CXCR6 | |
| SCHEMBL13490680 | 0.84 | ADORA1 (0.46) | RAB9ANPC1CHEK1CXCR6POLB | |
| SCHEMBL13490710 | 0.83 | CHRM4 (0.47) | RAB9ANPC1CHEK1CXCR6 | |
| SCHEMBL14192843 | 0.83 | CHRM4 (0.47) | RAB9ANPC1CHEK1CXCR6 | |
| SCHEMBL13490701 | 0.83 | HTR2B (0.46) | RAB9ANPC1MAPTCHEK1CXCR6 | |
| SCHEMBL13490684 | 0.82 | EPHX2 (0.50) | CHEK1CXCR6POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | RAB9A 1662/4885NPC1 3250/4885MAPT 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.